Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way

Ann Oncol. 2019 Mar 1;30(3):347-348. doi: 10.1093/annonc/mdz040.

Authors

M L Telli¹, S Vinayak²

Affiliations

¹ Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford. Electronic address: mtelli@stanford.edu.
² Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle, USA.

PMID: 30753266
DOI: 10.1093/annonc/mdz040

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
B7-H1 Antigen*
Cohort Studies
Humans
Triple Negative Breast Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
pembrolizumab